MMC doubles down on digital health business, Habitual, to help reverse type 2 diabetes

We’re excited to be backing Ian and Napala again alongside Atlantic Food Labs, Seedcamp and the Oxford Seed Fund.

Habitual’s mission is to end type 2 diabetes by combining digital therapeutics with a nutritionally-complete food product—an unprecedented combination of two clinically-validated tools that holds the potential to prevent and reverse lifestyle disease across the globe. This latest funding will be used to fuel user growth, increase team size, and undertake clinical research trials.

There’s never been a better time to build a digital health company, particularly in the diabetes space. With skyrocketing rates of chronic disease crippling our healthcare systems, the COVID-19 pandemic accelerating adoption of digital healthcare interventions, and increasing patient awareness of the importance of a healthy, balanced lifestyle, we’re not only hoping to build a massive business—but also to help millions of people across the world to live longer, happier lives.

NAPALA PRATINICO-FOUNDER & COO, HABITUAL

Apart from Covid-19, type 2 diabetes is the most pressing healthcare problem facing modern society. In the UK, one in 10 people over the age of 40 is diagnosed with type 2 diabetes. Of these, 60% will suffer from a complication of the disease, with major risks including amputation, heart attack, and stroke.

But recent evidence shows that 45-60%, of people with type 2 diabetes can completely reverse the condition through a combination of diet and behavioural change. The reversibility of type 2 diabetes holds the potential to not only change millions of lives across the world, but also to save healthcare systems billions of dollars. Habitual is working hard to deliver a scaled digital intervention to the millions of patients that need it.

Read more on Habitual’s raise via TechCrunch.

Digital health remains a key area of focus for MMC, if you’re a founder in this space and think we could help, get in touch.